Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease [Yahoo!...
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Yahoo! Finance
Based on these data, the Company does not plan further development of dalzanemdor CAMBRIDGE, Mass., November 20, 2024 BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84. Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences in participants treated with dalzanemdor compared to placebo. Based on these results, the Company does not plan further development of dalzanemdor. "We are disappointed by the results of the DIMENSION Study, especially for the individuals and families affected by Huntington's Disease who have long awaited new treatment
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More [Yahoo! Finance]Yahoo! Finance
- SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $10.00 to $9.00. They now have a "hold" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
SAGE
Earnings
- 10/29/24 - Miss
SAGE
Sec Filings
- 11/20/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form 4
- SAGE's page on the SEC website